Blueberry Therapeutics provides regulatory update on Phase 2b trial

Alderley Park, 24 May 2022 – Blueberry Therapeutics has reported significant progress in its Phase 2b European trial of BB2603 in onychomycosis (BBTAF202).

The COVID-19 pandemic led to operational challenges in all 3 participating countries (Germany, Poland and Czech Republic) – including a trial pause to ensure patient and site staff safety.

Blueberry has worked creatively to implement strategies to boost patient numbers and minimise delays, including protocol changes and roll-out of a multi-media advertising campaign to increase awareness of clinical research in this area. These have required multiple regulatory submissions to notify or obtain approval from Ethics Committees and Competent Authorities.

The company is delighted to share that the final approval in this jigsaw has been received and recruitment is expected to complete in July 2022. The primary endpoint is expected 1Q23.